Targeting the urokinase plasminogen activation pathway reduces PDAC cancer progression.

被引：0
|
作者：
Chowdhury, Nayela N. [1 ]
Yang, Yi [2 ]
Shen, Yingnan [3 ]
Davey, Keely G. [2 ]
Han, Bumsoo [3 ]
Wolberg, Alisa [2 ]
Flick, Matthew J. [2 ]
Fishel, Melissa L. [1 ]
机构：
[1] Indiana Univ, Sch Med, Indianapolis, IN 46208 USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Purdue Univ, W Lafayette, IN 47907 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2002
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis
    Brungs, Daniel
    Chen, Julia
    Aghmesheh, Morteza
    Vine, Kara L.
    Becker, Therese M.
    Carolan, Martin G.
    Ranson, Marie
    ONCOTARGET, 2017, 8 (14) : 23099 - 23109
  • [32] Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor
    Nozaki, S
    Endo, Y
    Nakahara, H
    Yoshizawa, K
    Hashiba, Y
    Kawashiri, S
    Tanaka, A
    Nakagawa, K
    Matsuoka, Y
    Kogo, M
    Yamamoto, E
    ORAL ONCOLOGY, 2005, 41 (10) : 971 - 977
  • [33] The Stress Polarity Signaling Pathway Resists Fusobacterium - mediated Colorectal Cancer Initiation and Progression.
    Sayed, I. M.
    Swanson, L. A.
    Mittal, Y. R.
    Dunkel, Y.
    Joosen, P.
    Sahoo, D.
    Ghosh, P.
    Das, S.
    MOLECULAR BIOLOGY OF THE CELL, 2018, 29 (26)
  • [34] RETRACTION: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer (Retraction of Vol 67, Pg 930, 2007)
    Pulukuri, S. M. K.
    Estes, N.
    Patel, J.
    Rao, J. S.
    CANCER RESEARCH, 2018, 78 (12) : 3397 - 3397
  • [35] Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis
    Xu, Zhen
    Meng, Li-Li
    Lin, Jizong
    Ling, Yunbiao
    Chen, Shu-xian
    Lin, Nan
    ONCOTARGETS AND THERAPY, 2015, 8 : 2493 - 2502
  • [36] Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer
    Konecny, G
    Untch, M
    Pihan, A
    Kimmig, R
    Gropp, M
    Stieber, P
    Hepp, H
    Slamon, D
    Pegram, M
    CLINICAL CANCER RESEARCH, 2001, 7 (06) : 1743 - 1749
  • [37] ELEVATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DURING PROGRESSION AND METASTASIS IN COLORECTAL-CANCER
    TANAKA, T
    KONNO, H
    NISHINO, N
    BABA, S
    URANO, T
    TAKADA, Y
    TAKADA, A
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1038 - 1038
  • [38] Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review
    Camedda, Riccardo
    Frantellizzi, Viviana
    Danieli, Roberta
    De Vincentis, Giuseppe
    Filippi, Luca
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (3-4) : 137 - 145
  • [39] Targeting the Urokinase Plasminogen Activator Receptor With a Monoclonal Antibody Impairs the Growth of Human Colorectal Cancer in the Liver
    Van Buren, George, II
    Gray, Michael J.
    Dallas, Nikolaos A.
    Xia, Ling
    Lim, Sherry J.
    Fan, Fan
    Mazar, Andrew P.
    Ellis, Lee M.
    CANCER, 2009, 115 (14) : 3360 - 3368
  • [40] Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway
    Estrella, Veronica C.
    Eder, Astrid M.
    Liu, Shuying
    Pustilnik, Terri B.
    Tabassam, Fazal H.
    Claret, Francois X.
    Gallick, Gary E.
    Mills, Gordon B.
    Wiener, Jon R.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (02) : 441 - 449
12345